Down-regulated NOD2 by immunosuppressants in peripheral blood cells in patients with SLE reduces the muramyl dipeptide-induced IL-10 production

PLoS ONE

Volumn 6, Issue 8, 2011, Pages

  Yu, Shui Lian ^a   Wong, Chun Kwok ^a   Wong, Purple Tsz Yan ^a   Chen, Da Peng ^a,b   Szeto, Cheuk Chun ^a   Li, Edmund K ^a   Tam, Lai Shan ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b CHILDREN S HOSPITAL OF CHONGQING MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CASPASE RECRUITMENT DOMAIN PROTEIN 15; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; HYDROXYCHLOROQUINE; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; MURAMYL DIPEPTIDE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; CYTOKINE; IL10 PROTEIN, HUMAN; N ACETYLMURAMYLALANYL DEXTRO ISOGLUTAMINE;

ADULT; ARTICLE; B LYMPHOCYTE; BLOOD CELL; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE DURATION; DOWN REGULATION; DRUG MECHANISM; FEMALE; HUMAN; HUMAN CELL; IMMUNOSUPPRESSIVE TREATMENT; MONOCYTE; MYELOID DENDRITIC CELL; PLASMACYTOID DENDRITIC CELL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INDUCTION; PROTEIN LOCALIZATION; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE; BACTERIUM; BIOSYNTHESIS; BLOOD; CASE CONTROL STUDY; DRUG EFFECT; GENETICS; IMMUNE SYSTEM; IMMUNOLOGY; INNATE IMMUNITY; METABOLISM; MIDDLE AGED; PATHOLOGY;

BACTERIA (MICROORGANISMS);

ACETYLMURAMYL-ALANYL-ISOGLUTAMINE; ADULT; BACTERIA; BLOOD CELLS; CASE-CONTROL STUDIES; CYTOKINES; DOWN-REGULATION; HUMANS; IMMUNE SYSTEM; IMMUNITY, INNATE; IMMUNOSUPPRESSIVE AGENTS; INTERLEUKIN-10; LUPUS ERYTHEMATOSUS, SYSTEMIC; MIDDLE AGED; NOD2 SIGNALING ADAPTOR PROTEIN; YOUNG ADULT;

EID: 80051849025     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0023855     Document Type: Article

References (71)

1. Mok CC, Lau CS, (2003) Pathogenesis of systemic lupus erythematosus. J Clin Pathol 56: 481-490.
2. Verdolini R, Bugatti L, Giangiacomi M, Nicolini M, Filosa G, et al. (2002) Systemic lupus erythematosus induced by Epstein-Barr virus infection. Br J Dermatol 146: 877-881.
3. Tomita H, Yamada M, Sekigawa I, Yoshiike T, Iida N, et al. (2003) Systemic lupus erythematosus-like autoimmune abnormalities induced by bacterial infection. Clin Exp Rheumatol 21: 497-499.
4. Lerner MR, Andrews NC, Miller G, Steitz JA, (1981) Two small RNAs encoded by Epstein-Barr virus and complexed with protein are precipitated by antibodies from patients with systemic lupus erythematosus. Proc Natl Acad Sci U S A 78: 805-809.
5. Fukata M, Vamadevan AS, Abreu MT, (2009) Toll-like receptors (TLRs) and Nod-like receptors (NLRs) in inflammatory disorders. Semin Immunol 21: 242-253.
6. Ospelt C, Brentano F, Jungel A, Rengel Y, Kolling C, et al. (2009) Expression, regulation, and signaling of the pattern-recognition receptor nucleotide-binding oligomerization domain 2 in rheumatoid arthritis synovial fibroblasts. Arthritis Rheum 60: 355-363.
7. Wong CK, Wong PT, Tam LS, Li EK, Chen DP, et al. (2009) Activation profile of Toll-like receptors of peripheral blood lymphocytes in patients with systemic lupus erythematosus. Clin Exp Immunol 159: 11-22.
8. Marshak-Rothstein A, (2006) Toll-like receptors in systemic autoimmune disease. Nat Rev Immunol 6: 823-835.
9. Werling D, Jungi TW, (2003) TOLL-like receptors linking innate and adaptive immune response. Vet Immunol Immunopathol 91: 1-12.
10. Komatsuda A, Wakui H, Iwamoto K, Ozawa M, Togashi M, et al. (2008) Up-regulated expression of Toll-like receptors mRNAs in peripheral blood mononuclear cells from patients with systemic lupus erythematosus. Clin Exp Immunol 152: 482-487.
11. Creagh EM, O'Neill LA, (2006) TLRs, NLRs and RLRs: a trinity of pathogen sensors that co-operate in innate immunity. Trends Immunol 27: 352-357.
12. Inohara, Chamaillard, McDonald C, Nunez G, (2005) NOD-LRR proteins: role in host-microbial interactions and inflammatory disease. Annu Rev Biochem 74: 355-383.
13. Kufer TA, Fritz JH, Philpott DJ, (2005) NACHT-LRR proteins (NLRs) in bacterial infection and immunity. Trends Microbiol 13: 381-388.
14. Koval'chuk DV, Khoreva MV, Nikonova AS, (2011) [Recognition receptors of innate immunity (NLR, RLr, and CLR)]. Zh Mikrobiol Epidemiol Immunobiol pp. 93-100.
15. Kanneganti TD, Lamkanfi M, Nunez G, (2007) Intracellular NOD-like receptors in host defense and disease. Immunity 27: 549-559.
16. Joosten LA, Heinhuis B, Abdollahi-Roodsaz S, Ferwerda G, Lebourhis L, et al. (2008) Differential function of the NACHT-LRR (NLR) members Nod1 and Nod2 in arthritis. Proc Natl Acad Sci U S A 105: 9017-9022.
17. Strober W, Murray PJ, Kitani A, Watanabe T, (2006) Signalling pathways and molecular interactions of NOD1 and NOD2. Nat Rev Immunol 6: 9-20.
18. Ferreiros-Vidal I, Garcia-Meijide J, Carreira P, Barros F, Carracedo A, et al. (2003) The three most common CARD15 mutations associated with Crohn's disease and the chromosome 16 susceptibility locus for systemic lupus erythematosus. Rheumatology (Oxford) 42: 570-574.
19. Hitotsumatsu O, Ahmad RC, Tavares R, Wang M, Philpott D, et al. (2008) The ubiquitin-editing enzyme A20 restricts nucleotide-binding oligomerization domain containing 2-triggered signals. Immunity 28: 381-390.
20. Graham RR, Cotsapas C, Davies L, Hackett R, Lessard CJ, et al. (2008) Genetic variants near TNFAIP3 on 6q23 are associated with systemic lupus erythematosus. Nat Genet 40: 1059-1061.
21. Musone SL, Taylor KE, Lu TT, Nititham J, Ferreira RC, et al. (2008) Multiple polymorphisms in the TNFAIP3 region are independently associated with systemic lupus erythematosus. Nat Genet 40: 1062-1064.
22. Han JW, Zheng HF, Cui Y, Sun LD, Ye DQ, et al. (2009) Genome-wide association study in a Chinese Han population identifies nine new susceptibility loci for systemic lupus erythematosus. Nat Genet 41: 1234-1237.
23. Adrianto I, Wen F, Templeton A, Wiley G, King JB, et al. (2011) Association of a functional variant downstream of TNFAIP3 with systemic lupus erythematosus. Nat Genet 43: 253-258.
24. Hochberg MC, (1997) Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 40: 1725.
25. Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH, (1992) Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum 35: 630-640.
26. Gladman DD, Urowitz MB, Goldsmith CH, Fortin P, Ginzler E, et al. (1997) The reliability of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index in patients with systemic lupus erythematosus. Arthritis Rheum 40: 809-813.
27. Schiffenbauer J, Simon LS, (2004) Randomized controlled trials in systemic lupus erythematosus: what has been done and what do we need to do? Lupus 13: 398-405.
28. Petri M, Genovese M, Engle E, Hochberg M, (1991) Definition, incidence, and clinical description of flare in systemic lupus erythematosus. A prospective cohort study. Arthritis Rheum 34: 937-944.
29. Lun SW, Wong CK, Ko FW, Hui DS, Lam CW, (2009) Expression and functional analysis of toll-like receptors of peripheral blood cells in asthmatic patients: implication for immunopathological mechanism in asthma. J Clin Immunol 29: 330-342.
30. Zandman-Goddard G, Shoenfeld Y, (2003) SLE and infections. Clin Rev Allergy Immunol 25: 29-40.
31. Tam LS, Chan AY, Chan PK, Chang AR, Li EK, (2004) Increased prevalence of squamous intraepithelial lesions in systemic lupus erythematosus: association with human papillomavirus infection. Arthritis Rheum 50: 3619-3625.
32. Zandman-Goddard G, Shoenfeld Y, (2005) Infections and SLE. Autoimmunity 38: 473-485.
33. Means TK, Wang S, Lien E, Yoshimura A, Golenbock DT, et al. (1999) Human toll-like receptors mediate cellular activation by Mycobacterium tuberculosis. J Immunol 163: 3920-3927.
34. Netea MG, Kullberg BJ, Galama JM, Stalenhoef AF, Dinarello CA, et al. (2002) Non-LPS components of Chlamydia pneumoniae stimulate cytokine production through Toll-like receptor 2-dependent pathways. Eur J Immunol 32: 1188-1195.
35. Travassos LH, Carneiro LA, Girardin SE, Boneca IG, Lemos R, et al. (2005) Nod1 participates in the innate immune response to Pseudomonas aeruginosa. J Biol Chem 280: 36714-36718.
36. Masumoto J, Yang K, Varambally S, Hasegawa M, Tomlins SA, et al. (2006) Nod1 acts as an intracellular receptor to stimulate chemokine production and neutrophil recruitment in vivo. J Exp Med 203: 203-213.
37. Shin JN, Eissa NT, (2010) Autophagy gets the 'NOD' to enhance bacterial handling and antigen presentation. Immunol Cell Biol 88: 343-345.
38. Petterson T, Jendholm J, Mansson A, Bjartell A, Riesbeck K, et al. (2011) Effects of NOD-like receptors in human B lymphocytes and crosstalk between NOD1/NOD2 and Toll-like receptors. J Leukoc Biol 89: 177-187.
39. Lecat A, Piette J, Legrand-Poels S, (2010) The protein Nod2: an innate receptor more complex than previously assumed. Biochem Pharmacol 80: 2021-2031.
40. van Beelen AJ, Zelinkova Z, Taanman-Kueter EW, Muller FJ, Hommes DW, et al. (2007) Stimulation of the intracellular bacterial sensor NOD2 programs dendritic cells to promote interleukin-17 production in human memory T cells. Immunity 27: 660-669.
41. Dean GS, Tyrrell-Price J, Crawley E, Isenberg DA, (2000) Cytokines and systemic lupus erythematosus. Ann Rheum Dis 59: 243-251.
42. Doria A, Ghirardello A, Iaccarino L, Zampieri S, Punzi L, et al. (2004) Pregnancy, cytokines, and disease activity in systemic lupus erythematosus. Arthritis Rheum 51: 989-995.
43. Brennan FM, Feldmann M, (1996) Cytokines in autoimmunity. Curr Opin Immunol 8: 872-877.
44. Nicholson LB, Kuchroo VK, (1996) Manipulation of the Th1/Th2 balance in autoimmune disease. Curr Opin Immunol 8: 837-842.
45. Sabry A, Sheashaa H, El-Husseini A, Mahmoud K, Eldahshan KF, et al. (2006) Proinflammatory cytokines (TNF-alpha and IL-6) in Egyptian patients with SLE: its correlation with disease activity. Cytokine 35: 148-153.
46. Beebe AM, Cua DJ, de Waal Malefyt R, (2002) The role of interleukin-10 in autoimmune disease: systemic lupus erythematosus (SLE) and multiple sclerosis (MS). Cytokine Growth Factor Rev 13: 403-412.
47. Al-Mutairi S, Al-Awadhi A, Raghupathy R, Al-Khawari H, Sada P, et al. (2007) Lupus patients with pulmonary involvement have a pro-inflammatory cytokines profile. Rheumatol Int 27: 621-630.
48. Rosenzweig HL, Martin TM, Planck SR, Galster K, Jann MM, et al. (2008) Activation of NOD2 in vivo induces IL-1beta production in the eye via caspase-1 but results in ocular inflammation independently of IL-1 signaling. J Leukoc Biol 84: 529-536.
49. Hedl M, Abraham C, (2011) Distinct roles for Nod2 and autocrine IL-1{beta} in MDP-induced MAPK activation and cytokine secretion in human macrophages. J Biol Chem.
50. Voronov E, Dayan M, Zinger H, Gayvoronsky L, Lin JP, et al. (2006) IL-1 beta-deficient mice are resistant to induction of experimental SLE. Eur Cytokine Netw 17: 109-116.
51. Segal R, Bermas BL, Dayan M, Kalush F, Shearer GM, et al. (1997) Kinetics of cytokine production in experimental systemic lupus erythematosus: involvement of T helper cell 1/T helper cell 2-type cytokines in disease. J Immunol 158: 3009-3016.
52. Handwerger BS, Rus V, da Silva L, Via CS, (1994) The role of cytokines in the immunopathogenesis of lupus. Springer Semin Immunopathol 16: 153-180.
53. Macfarlane DE, Manzel L, (1998) Antagonism of immunostimulatory CpG-oligodeoxynucleotides by quinacrine, chloroquine, and structurally related compounds. J Immunol 160: 1122-1131.
54. Sun S, Rao NL, Venable J, Thurmond R, Karlsson L, (2007) TLR7/9 antagonists as therapeutics for immune-mediated inflammatory disorders. Inflamm Allergy Drug Targets 6: 223-235.
55. Van Beek MJ, Piette WW, (2001) Antimalarials. Dermatol Clin 19: 147-160, ix.
56. Khan N, Summers CW, Helbert MR, Arkwright PD, (2010) Effects of age, gender, and immunosuppressive agents on in vivo toll-like receptor pathway responses. Hum Immunol 71: 372-376.
57. Netea MG, Ferwerda G, de Jong DJ, Jansen T, Jacobs L, et al. (2005) Nucleotide-binding oligomerization domain-2 modulates specific TLR pathways for the induction of cytokine release. J Immunol 174: 6518-6523.
58. van Heel DA, Ghosh S, Butler M, Hunt KA, Lundberg AM, et al. (2005) Muramyl dipeptide and toll-like receptor sensitivity in NOD2-associated Crohn's disease. Lancet 365: 1794-1796.
59. Fiorentino DF, Bond MW, Mosmann TR, (1989) Two types of mouse T helper cell. IV. Th2 clones secrete a factor that inhibits cytokine production by Th1 clones. J Exp Med 170: 2081-2095.
60. de Waal Malefyt R, Haanen J, Spits H, Roncarolo MG, te Velde A, et al. (1991) Interleukin 10 (IL-10) and viral IL-10 strongly reduce antigen-specific human T cell proliferation by diminishing the antigen-presenting capacity of monocytes via downregulation of class II major histocompatibility complex expression. J Exp Med 174: 915-924.
61. Ding L, Linsley PS, Huang LY, Germain RN, Shevach EM, (1993) IL-10 inhibits macrophage costimulatory activity by selectively inhibiting the up-regulation of B7 expression. J Immunol 151: 1224-1234.
62. Rousset F, Garcia E, Defrance T, Peronne C, Vezzio N, et al. (1992) Interleukin 10 is a potent growth and differentiation factor for activated human B lymphocytes. Proc Natl Acad Sci U S A 89: 1890-1893.
63. Houssiau FA, Lefebvre C, Vanden Berghe M, Lambert M, Devogelaer JP, et al. (1995) Serum interleukin 10 titers in systemic lupus erythematosus reflect disease activity. Lupus 4: 393-395.
64. Lacki JK, Samborski W, Mackiewicz SH, (1997) Interleukin-10 and interleukin-6 in lupus erythematosus and rheumatoid arthritis, correlations with acute phase proteins. Clin Rheumatol 16: 275-278.
65. Noguchi E, Homma Y, Kang X, Netea MG, Ma X, (2009) A Crohn's disease-associated NOD2 mutation suppresses transcription of human IL10 by inhibiting activity of the nuclear ribonucleoprotein hnRNP-A1. Nat Immunol 10: 471-479.
66. Kobayashi KS, Chamaillard M, Ogura Y, Henegariu O, Inohara N, et al. (2005) Nod2-dependent regulation of innate and adaptive immunity in the intestinal tract. Science 307: 731-734.
67. Divangahi M, Mostowy S, Coulombe F, Kozak R, Guillot L, et al. (2008) NOD2-deficient mice have impaired resistance to Mycobacterium tuberculosis infection through defective innate and adaptive immunity. J Immunol 181: 7157-7165.
68. Tam LS, Li EK, Wong SM, Szeto CC, (2002) Risk factors and clinical features for tuberculosis among patients with systemic lupus erythematosus in Hong Kong. Scand J Rheumatol 31: 296-300.
69. Ribeiro FM, Szyper-Kravitz M, Klumb EM, Lannes G, Ribeiro FR, et al. (2010) Can lupus flares be associated with tuberculosis infection? Clin Rev Allergy Immunol 38: 163-168.
70. Hasan UA, Bates E, Takeshita F, Biliato A, Accardi R, et al. (2007) TLR9 expression and function is abolished by the cervical cancer-associated human papillomavirus type 16. J Immunol 178: 3186-3197.
71. Miyazaki M, Kanto T, Inoue M, Itose I, Miyatake H, et al. (2008) Impaired cytokine response in myeloid dendritic cells in chronic hepatitis C virus infection regardless of enhanced expression of Toll-like receptors and retinoic acid inducible gene-I. J Med Virol 80: 980-988.